RxDoctor Payments Data

Natalia Detrick

Nurse Practitioner · Clovis, CANPI 1700462025

Payments from drug & device makers

$10,558in general payments, 2019–2025

Across 336 payments — averaging $31.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$775
  • AstraZeneca$763
  • Genentech, Inc.$750
  • Gilead$672
  • Exelixis Inc.$546
  • plus $6K from 47 others

What the payments were for

  • Consulting fees$7507%
  • Food & beverage$8,01676%
  • Education$1,79217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,558 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$88,820
Medicare patients
474
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$10,871
XareltoRivaroxaban12$6,389
Atovaquone12$5,171
Potassium Chloride32$1,140
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$889
Lidocaine11$854
Ondansetron OdtOndansetron66$846
Acyclovir41$785
Dexamethasone64$711
Gabapentin20$310
Prochlorperazine Maleate41$304
Ondansetron Hcl35$222
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$173
Pantoprazole Sodium16$141
Lidocaine-PrilocaineLidocaine/Prilocaine11$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$185$10,87114 claims
Johnson & JohnsonXarelto$1,027$6,38912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Clovis

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →